These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20356699)

  • 1. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.
    Nguyen M; Eschenauer GA; Bryan M; O'Neil K; Furuya EY; Della-Latta P; Kubin CJ
    Diagn Microbiol Infect Dis; 2010 Jun; 67(2):180-4. PubMed ID: 20356699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae.
    Borer A; Saidel-Odes L; Eskira S; Nativ R; Riesenberg K; Livshiz-Riven I; Schlaeffer F; Sherf M; Peled N
    Am J Infect Control; 2012 Jun; 40(5):421-5. PubMed ID: 21906844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.
    Micozzi A; Gentile G; Minotti C; Cartoni C; Capria S; Ballarò D; Santilli S; Pacetti E; Grammatico S; Bucaneve G; Foà R
    BMC Infect Dis; 2017 Mar; 17(1):203. PubMed ID: 28283020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study.
    Falagas ME; Rafailidis PI; Kofteridis D; Virtzili S; Chelvatzoglou FC; Papaioannou V; Maraki S; Samonis G; Michalopoulos A
    J Antimicrob Chemother; 2007 Nov; 60(5):1124-30. PubMed ID: 17884829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak.
    Wiener-Well Y; Rudensky B; Yinnon AM; Kopuit P; Schlesinger Y; Broide E; Lachish T; Raveh D
    J Hosp Infect; 2010 Apr; 74(4):344-9. PubMed ID: 19783067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
    Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
    Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study.
    Liu SW; Chang HJ; Chia JH; Kuo AJ; Wu TL; Lee MH
    J Microbiol Immunol Infect; 2012 Apr; 45(2):113-9. PubMed ID: 22154994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state.
    Zuckerman T; Benyamini N; Sprecher H; Fineman R; Finkelstein R; Rowe JM; Oren I
    Bone Marrow Transplant; 2011 Sep; 46(9):1226-30. PubMed ID: 21057549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients.
    Kalpoe JS; Sonnenberg E; Factor SH; del Rio Martin J; Schiano T; Patel G; Huprikar S
    Liver Transpl; 2012 Apr; 18(4):468-74. PubMed ID: 22467548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients.
    Bleumin D; Cohen MJ; Moranne O; Esnault VL; Benenson S; Paltiel O; Tzukert K; Mor-Yosef Levi I; Ben-Dov IZ; Levi R; Bloch A; Haviv YS
    J Infect; 2012 Oct; 65(4):318-25. PubMed ID: 22722020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.
    Ny P; Nieberg P; Wong-Beringer A
    Am J Infect Control; 2015 Oct; 43(10):1076-80. PubMed ID: 26190386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.
    van Duin D; Cober E; Richter SS; Perez F; Kalayjian RC; Salata RA; Evans S; Fowler VG; Kaye KS; Bonomo RA
    J Antimicrob Chemother; 2015 Apr; 70(4):1203-11. PubMed ID: 25492391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
    Cprek JB; Gallagher JC
    Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.
    Borer A; Saidel-Odes L; Riesenberg K; Eskira S; Peled N; Nativ R; Schlaeffer F; Sherf M
    Infect Control Hosp Epidemiol; 2009 Oct; 30(10):972-6. PubMed ID: 19712030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients.
    Orsi GB; García-Fernández A; Giordano A; Venditti C; Bencardino A; Gianfreda R; Falcone M; Carattoli A; Venditti M
    J Hosp Infect; 2011 May; 78(1):54-8. PubMed ID: 21450365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.
    Paterson DL; Ko WC; Von Gottberg A; Mohapatra S; Casellas JM; Goossens H; Mulazimoglu L; Trenholme G; Klugman KP; Bonomo RA; Rice LB; Wagener MM; McCormack JG; Yu VL
    Clin Infect Dis; 2004 Jul; 39(1):31-7. PubMed ID: 15206050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.